Health (PRISME)

  • Presentation
  • Activities
  • Members
  • Publications

The PRISME team is composed of physicists, biochemists, biologists and radiotherapists. We specialize in multidisciplinary research aimed at developing, optimizing and controlling innovative radiotherapies, whether it be hadrontherapy or therapies using radioactive ion-emitting elements or nanoparticles. These radiotherapies aim to improve the treatment of certain cancers by increasing the effect of ionizing radiation in the tumor while minimizing its harmful effects on healthy tissues.

Our multidisciplinary approach aims to quantify, understand and predict the effect of ionizing radiation on living organisms from processes induced at extremely short times (attosecond) at small scales (atomic nucleus) to long-term consequences (years) at the patient level.
We therefore design and carry out irradiation experiments on targets ranging from molecules or cells to small animals and patient samples (tumor, blood). These experiments feed an important part of our activity which consists in modeling the effects of radiation on living organisms.

One of the innovative techniques of radiotherapy is hadrontherapy, which is to send
an ion beam on the tumors to destroy them. We are working, in particular using simulations, data processing and predictions, to improve these systems by having on-line control over irradiation using dedicated detectors. These tools also have applications in imaging.

The activities can be divided into three research areas:

Axis 1 aims to develop simulations and detectors to control patient irradiation by detecting the particles emitted during hadrontherapy treatment. These developments also offer application prospects in the field of diagnostic imaging.

Axis 2 focuses on the development of multi-scale models and simulations to describe and predict the physical, chemical and biological processes induced by irradiation. It also develops irradiation and dosimetric control means for the measurement of radiobiological effects.

Axis 3 quantifies by experiment the effects induced by irradiation with molecular, cellular, multicellular, in-vitro or in-vivo systems. It focuses on the specificities of innovative radiotherapies and the personalization of care.

PERMANENTS:

NON-PERMANENTS:

- DOCTORANTS / DOCTORAL STUDENTS:
    545 documents

    • Ane Etxebeste, Enrique Muñoz, Denis Dauvergne, J M Letang, M. Borja-Lloret, et al.. Comparison of efficiency and activity recovery coefficients of Compton and Anger cameras in Nuclear Medicine. IEEE Nuclear Science Symposium and Medical Imaging Conference (IEEE NSS MIC) 2021, Oct 2021, Virtual Yokohama, Japan, Oct 2021, Yokohama (virtual), Japan. ⟨hal-03473005⟩
    • M. Borja-Lloret, A. Etxebeste, G. Llosá, Enrique Muñoz, Ana Ros, et al.. Efficiency enhancement studies in a scintillator-based Compton camera for hadrontherapy. IEEE Nuclear Science Symposium and Medical Imaging Conference (IEEE NSS MIC) 2021, Oct 2021, Virtual Yokohama, Japan, Oct 2021, Yokohama (virtual), Japan. ⟨hal-03473025⟩
    • Magdalena Garbacz, Francesco Giuseppe Cordoni, Marco Durante, Jan Gajewski, Kamil Kisielewicz, et al.. Study of relationship between dose, LET and the risk of brain necrosis after proton therapy for skull base tumors. Radiotherapy & Oncology, 2021, 163, pp.143-149. ⟨10.1016/j.radonc.2021.08.015⟩. ⟨hal-03346790⟩
    • Rachel Delorme, Maria Pedrosa Rivera, Mario Alcocer-Avila, Victor Levrague, Gersende Alphonse, et al.. The PICTURE project: toward biological dose prediction of targeted radiotherapies emitting short-range ions, 19th International Congress on Neutron Capture Therapy. 19th International Congress on Neutron Capture Therapy, Sep 2021, Grenade, Spain. . ⟨hal-04305676⟩
    • A. Gauthier. Biopsies liquides et cultures de biopsies tumorales ex vivo pour la dĂ©termination de biomarqueurs prĂ©dictifs de la rĂ©ponse au traitemet par radio- et chimio-thĂ©rapie dans les cancers des VADS. AssemblĂ©e GĂ©nĂ©rale GDR MI2B 2021, Sep 2021, Ecully, France. ⟨in2p3-04956694⟩
    • A.-S. Wozny. Implication d’HIF-1α dans la rĂ©paration des cassures double-brin de l’ADN induites par une irradiation photonique et par ions carbone. AssemblĂ©e GĂ©nĂ©rale GDR MI2B 2021, Sep 2021, Ecullly, France. ⟨in2p3-04956706⟩
    • Amalia Jacquot, CĂ©line Chauleur, Anne-Sophie Russel-Robillard, Fabien Tinquaut, Sandrine Sotton, et al.. MRI accuracy and interobserver agreement in locally advanced cervix carcinoma. British Journal of Radiology, 2021, 94 (1125), ⟨10.1259/bjr.20210197⟩. ⟨hal-04826687⟩
    • G. Muggiolu, S. Libert, B. Treillard, G. Alfonse, P. Philouze, et al.. PO-1929 Identification of DNA repair-based biomarkers related to treatment outcome in head and neck cancers. ESTRO, Aug 2021, Madrid, Spain. pp.S1643-S1644, ⟨10.1016/s0167-8140(21)08380-8⟩. ⟨hal-03450014⟩
    • Anne-Sophie Wozny, Arnaud Gauthier, Gersende Alphonse, CĂ©line MalĂ©sys, Virginie Varoclier, et al.. Involvement of HIF-1α in the Detection, Signaling, and Repair of DNA Double-Strand Breaks after Photon and Carbon-Ion Irradiation. Cancers, 2021, 13 (15), pp.3833. ⟨10.3390/cancers13153833⟩. ⟨hal-03326508⟩
    • Jean-Baptiste Guy, Sophie Espenel, Safa Louati, Arnaud Gauthier, Max-Adrien Garcia, et al.. Combining radiation to EGFR and Bcl-2 blockade: a new approach to target cancer stem cells in head and neck squamous cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2021, 147 (7), pp.1905-1916. ⟨10.1007/s00432-021-03593-8⟩. ⟨hal-03258241⟩

    Powered by HAL logo